Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

588.85INR
3:27pm IST
Price Change (% chg)

Rs-24.05 (-3.92%)
Prev Close
Rs612.90
Open
Rs624.00
Day's High
Rs624.00
Day's Low
Rs578.95
Volume
5,183,178
Avg. Vol
1,785,421
52-wk High
Rs639.10
52-wk Low
Rs366.50

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin... (more)

Overall

Beta: 0.53
Market Cap (Mil.): Rs492,110.50
Shares Outstanding (Mil.): 802.92
Dividend: 2.00
Yield (%): 0.33

Financials

  CIPL.NS Industry Sector
P/E (TTM): 35.46 32.84 33.70
EPS (TTM): 17.28 -- --
ROI: -- 18.11 17.35
ROE: -- 18.82 18.21
Search Stocks

UPDATE 2-India caps prices of 36 more drugs to improve access -govt official

* Local firms Cipla, Ranbaxy, Cadila among companies affected

19 Sep 2014

Cipla grants Salix rights for Rifaximin

MUMBAI - Drugmaker Cipla Ltd has agreed to grant U.S.-based Salix Pharmaceuticals Ltd rights relating to the "Rifaximin complexes" patent family controlled by Cipla, the two companies said on Thursday.

18 Sep 2014

India's Cipla grants Salix rights for Rifaximin

MUMBAI, Sept 18 - Indian drugmaker Cipla Ltd has agreed to grant U.S.-based Salix Pharmaceuticals Ltd rights relating to the "Rifaximin complexes" patent family controlled by Cipla, the two companies said on Thursday.

18 Sep 2014

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others

NEW DELHI/MUMBAI - U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations.

15 Sep 2014

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others

NEW DELHI/MUMBAI, Sept 15 - U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.

15 Sep 2014

UPDATE 1-Poor patients in India facing HIV/AIDS drug shortages

* Cipla named as one of firms dropping out of tender process

04 Sep 2014

India's BSE index surges past 27,000 to third consecutive record high

* BSE index gains 0.57 pct; NSE ends 0.69 pct higher * Cipla jumps as much as 8.7 pct after key generic launch By Abhishek Vishnoi MUMBAI, Sept 2 - India's benchmark BSE index on Tuesday surged past the psychologically key level of 27,000 to a third consecutive record high as blue-chips such as HDFC Bank gained after recent data raised hopes about the economy. The BSE milestone comes a day after the broader NSE index surpassed the 8,000 level for the first time, provi

02 Sep 2014

Cipla jumps 8.7 percent after key generic launch

Reuters Market Eye - Shares in Cipla Ltd on Tuesday rose as much as 8.7 percent to a record high of 575 rupees after the drugmaker launched an anti-asthma inhaler in Germany and Sweden.

02 Sep 2014

MARKET EYE -India's Cipla jumps 8.7 pct after key generic launch

* Cipla Ltd rises as much as 8.7 percent to a record high of 575 rupees. * The drug maker launches an anti-asthma inhaler in Germany and Sweden * The inhaler is a generic version of GlaxoSmithKline Plc's Advair. * Emkay Global upgrades to "buy" from "accumulate" with a target of 671 rupees. * Overall addressable opportunity of generic Advair is $800 million in Europe, Emkay says. (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

02 Sep 2014

India's Cipla launches copy of GSK's top asthma drug in Germany, Sweden

MUMBAI - India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair, a move that will further dent sales of the British firm's top-selling product.

01 Sep 2014

Earnings vs. Estimates

Search Stocks